Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

about

Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

Item

http://www.wikidata.org/entity/Q48223561

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

@en

Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

@nl

type

Item

label

Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

@en

Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

@nl

prefLabel

Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

@en

Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

@nl

P1476

Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

@en

P2093

Mia G Angeli

http://www.w3.org/2001/XMLSchema#string

Novera Alam

http://www.w3.org/2001/XMLSchema#string

P2860

Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.

Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.

Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes.

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.

Clinical Pharmacokinetics of Paritaprevir.

Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.

Mechanisms and Consequences of Drug-Drug Interactions.

Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.

P304

1794-1801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JPHP.12821

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David J Greenblatt

P577

2017-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28990653

http://www.w3.org/2001/XMLSchema#string